Residents in care homes are more likely to be prescribed multiple medicines yet often have little involvement in these prescribing decisions.
(401 medicines; 57%), resident not wanting medicine after risks and benefits were explained (120 medicines; 17%), and safety concerns (42 medicines; 6%).
The net annualised savings against the medicines budget were £77,703 or £184 per person reviewed. The cost of delivering the intervention was £32,670 (pharmacist, GP, POAS consultant, and care home nurse time) for 422 residents; for every £1 invested, £2.38 could be released from the medicines budget.
This project demonstrated that a multidisciplinary medication review with a pharmacist, doctor, and care home nurse can safely reduce inappropriate medication in elderly care home residents.
Problem
A pilot project involving a pharmacist and general practitioner (GP) in medication reviews was undertaken for 37 residents in a local care home, taking into consideration current co-morbidities, prognosis and resident/family/carer views. The reviews highlighted that many residents (over two thirds) were taking medicines that had no current indication or the medication had no purpose given the co-morbidity. In total, 114 medicines were stopped. A specific case highlighted issues around lack of review and appropriate prescribing.
An 85 year old lady in a care home, who was bed bound and unable to communicate or make decisions, was prescribed 11 regular medicines including medicines to prevent fractures and cardiovascular disease, as well as antidepressants, hypnotics, and antipsychotics for agitation. After discussion with family, preventative medicines were stopped; her agitation resolved and psychotropic medicines were gradually withdrawn with no adverse events.
Clear guidelines exist for starting medicines but there is less guidance for stopping medicines. Prescribers face ethical, legal, and professional challenges when deprescribing. Furthermore, patients are given little opportunity to be involved in decisions about medicines.
Background
Many of the medicines prescribed to older patients are inappropriate and potentially harmful. [1, 2] Care home residents are at a high risk from medicines-related harm as they are older and frailer than the general population, usually take a large number of and often inappropriate prescribing, lack of structured review, long medication rounds, and lack of resident involvement in decisions about medicines. [4] Stopping medicines can be perceived as problematic as there is less published guidance available when compared to starting medicines.
Involving patients in shared decision making (SDM) about medicines may not be routine practice; barriers include time constraints and the perception among clinicians that SDM is not appropriate for their patients. [5] One study in a care home setting showed that all residents interviewed accepted without question doctors' and nurses' control of prescribing and administration. [6] While prescribers often follow evidence-based guidelines, these guidelines do not necessary reflect the preferences of patients and do not seek to involve them. [7] Studies have highlighted clinician perceptions of patients being attached to their usual medicines, and reluctance to interfere with previous decisions, which contributes to inappropriate prescribing. [8] 
Baseline measurement
Prior to the project, an audit of 49 residents was carried out at a care home in North Tyneside using the STOPP (Screening Tool of Older People's potentially inappropriate Prescriptions) criteria [1] ; 63% (31 residents) were taking one or more inappropriate medicines as defined by the STOPP tool. In a second care home, medication reviews were undertaken by a pharmacist, GP and care home nurse team using a pragmatic approach which took into consideration current co-morbidities, prognosis, and patient/family/carer views. Thirty-seven residents were reviewed and 114 medicines were stopped. All residents were monitored for adverse events by care home staff following the intervention and followed up by the pharmacist to ensure suspected negative effects were identified and safely managed. The process was iterative, with rapid feedback from each clinic being used to improve the process.
Strategy
The first four MDT meetings comprised a pharmacist, care home nurse, general medical practitioner, with nursing and/or consultant input from POAS. Through qualitative interviews with the team it became apparent that the psychiatry team was not needed for the majority of planned interventions as they involved medicines for a range of chronic physical conditions. An alternative model for POAS involvement was developed: residents known to the psychiatry team were highlighted to the team, new residents were referred into the team using existing referral mechanisms or email/ telephone advice was sought. This model provided a better use of psychiatry resources.
The team recognised from initial reviews that involving all residents in decisions was a challenge. In the first PDSA (plan, do, study, act) cycle it was identified that many residents lacked capacity for decisions about medicines and many families were difficult to engage. Following further discussion a four level resident involvement framework was developed as follows: 
Results
Reviews were undertaken at 12 main care homes (fully reviewed) and eight additional care homes (partially reviewed). The majority (n=15) were mixed nursing and residential homes, with three being residential and two nursing only.
Altogether, 422 residents were reviewed within 16 general practices. In 382 residents (90.5%) there were 1346 interventions, with only 9.5% of residents not requiring any intervention.
The most common intervention was to stop medicines (704 medicines) in 298 residents (70.6%). On average 1.7 medicines were stopped for every resident reviewed (range 0 to 9 medicines; SD 1.7). This was equivalent to a 17.4% reduction in medicines prescribed. The most common reasons for stopping medicines were no current indication (57%) and residents not wanting to take the medicine after risks and benefits were explained (17%). Forty-one medicines (6%) were stopped because of safety concerns.
Following changes to medicines, nine residents (2.1%) experienced potential adverse events. All events were reversible and did not result in harm to the patient.
A patient involvement framework was developed so that all residents could be involved in decisions. Of the 382 residents needing an intervention, 352 were asked to be involved in decisions; 30 residents received interventions which did not require a shared decision about medicine management. Fifty-seven residents (16%) were fully involved in decisions about medicines.
Families were involved for 137 residents (39%) and letters were sent to families of 141 (40%) residents. None of the interventions outlined in the letters were challenged by the families. Advocacy was needed for 16 (4.5%) residents.
The time taken to administer medicines was collected pre-and postmedication review at eight similarly sized care homes. On average, 56.7 minutes per day or 6.6 hours per week of nursing was redirected from medicines administration to resident care.
Interviews with residents, families, care home staff and professionals were carried out. The main themes from interviews with residents and families were perceptions of over-prescribing, lack of understanding of the review process, and having no involvement in decisions about medicines. Medication reviews and the opportunity to be involved were highlighted as being valued by families. Care home staff noted medication administration rounds and lack of regular structured review as big concerns. The main benefits from the medication reviews were seen to be resident involvement and reduction in medicines burden. GPs acknowledged that they do not routinely involve patients in decisions and time was cited as a barrier to detailed reviews. They felt the reviews improved relationships between themselves, patients and care homes and that involving patients was a positive move. GPs and care home staff valued the contribution of the pharmacist in the review process. All staff valued the role that patients could play in their own health. Limited data on medicines returned for destruction from the pharmacy supplying four care homes showed a downwards trend in medicines waste. There are data for one care home suggesting that reduction in waste was sustained eight months post-review.
To perform a basic health economic evaluation, we used the total number of interventions made and number of interventions where medicines were stopped as a marker for quality. We also factored in the net savings from changing, stopping or starting medicines.
Model 2 data should be interpreted with caution as only 21 residents were reviewed using this model. The number of interventions and medicines stopped were lowest in model 3. 
Lessons and limitations
The aims and objectives we set out to achieve were met. The project benefited from strong relationships between the clinical and support teams and key stakeholders. A targeted communications strategy ensured maximum exposure of the project. Having a wide steering group ensured that all relevant professionals and patients were represented.
Furthermore, the clinical pharmacists involved were experienced independent prescribers who were competent to make autonomous decisions. The POAS consultant and team were fully dedicated to the project and had built in capacity to manage the additional workload that the project generated. Care home nurses and general practices were supportive and allowed full access to medical records.
We maximised patient involvement by first assuming all residents had capacity for medicines decisions. Final decisions were subsequently made by families or advocates only where residents lacked capacity. In cases where residents' families did not wish to be involved, we wrote to them in lay language explaining the interventions.
The review process was affected by variation in medical practices' involvement in care home reviews. This led to inconsistency in availability of GPs to participate in the MDT discussion. To account for this, the team accepted that one approach could not be sustained across all the practices we were planning to work with.
Through consultation with lead GPs and practice managers we identified four models of GP involvement. The differential analysis of the models demonstrated that GP involvement in the MDT resulted in the greatest number of interventions. This may have limited the full potential of interventions and savings that could have been achieved had a GP be present in every review. Despite this, our development of other effective models of working has made the service more sustainable.
We have successfully shown an economic benefit to structured medication reviews where residents are involved in decisions. We further believe that our process can be upscaled and used to improve care for care home residents across the United Kingdom.
The process that we have developed is also applicable to elderly patients who are not in care homes (eg sheltered housing or in their own homes) who have similar problems with inappropriate prescribing and lack of involvement. The shared decision making methodology could potentially be adopted for all those working with patients, irrespective of care setting.
Limitations of this project include the fact that the care homes chosen were not randomly selected. A number of the qualitative interviews were taken from residents of families who expressed interest in taking part. Hence there may be bias in their observations. Any interventions, including those identified as potentially causing harm, were not independently agreed or categorised according to the likelihood of harm. The subjective nature of these decisions could have limited their accuracy against more robust methods used to identify potential harm. [3] The assessment of each resident's capacity to make decisions about medicines was based on the opinions of the care home nurse and/or GP who were present during the review. This lack of formal assessment created potential inaccuracy in the documented status.
To test this, the POAS team performed both formal and informal assessments on a selection of residents in a project care home.
The results showed that the informal assessment was accurate for the vast majority of cases. Although this goes some way to improve confidence in the methodology used, it is unclear whether the same would be true for the remainder of residents within the project.
Where medicines were started, changed or stopped, we estimated annualised costs and savings. The project did not follow-up each intervention to ensure the change was sustained for the following 12 months or whether the resident was still alive. A 2011 study commissioned by BUPA highlighted that residents had only a 55% chance of surviving the first year after admission. [9] However, as the average length of stay from that study was 801 days, and the overall savings from stopped medicines would continue for the life of that resident, we deemed the use of annualised savings to be reasonable.
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Drug costs were taken from the Drug Tariff™ at the time of the review. There may be inaccuracies in annual prices calculated as they may change over the course of the year.
Data on medicines waste was limited with information for four care homes at two months post-review and only one care home at eight months post-review. Further work is needed to ensure the suggested reduction in waste is replicated and sustained across all care homes within the study.
Conclusion
In conclusion, a structured multidisciplinary review of medicines in a care home setting where residents and/or their families are fully involved in decisions can improve quality of prescribing and reduce healthcare costs.
